​

Cogent Biosciences (COGT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

COGT Stock Forecast

Cogent Biosciences (COGT) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $48.13, with a high of $60.00 and a low of $35.00. This represents a 36.23% increase from the last price of $35.33.

$5 $16 $27 $38 $49 $60 High: $60 Avg: $48.13 Low: $35 Last Closed Price: $35.33

COGT Stock Rating

Cogent Biosciences stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (83.33%), 2 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 2 10 0 Strong Sell Sell Hold Buy Strong Buy

COGT Price Target Upside V Benchmarks

TypeNameUpside
StockCogent Biosciences36.23%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2411
Avg Price Target$43.50$49.75$41.00
Last Closing Price$35.33$35.33$35.33
Upside/Downside23.12%40.82%16.05%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26292--13
Feb, 26292--13
Jan, 26282--12
Dec, 25282--12
Nov, 25454--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 19, 2026Robert W. Baird$35.00$38.29-8.59%-0.93%
Feb 18, 2026Piper Sandler$52.00$37.6238.22%47.18%
Jan 07, 2026Michael YeeUBS$60.00$34.7872.51%69.83%
Jan 06, 2026H.C. Wainwright$52.00$34.2651.78%47.18%
Dec 08, 2025Jefferies$48.00$39.9720.09%35.86%
Nov 11, 2025Chris RaymondRaymond James$60.00$32.4684.84%69.83%
Nov 10, 2025Stifel Nicolaus$40.00$34.9714.38%13.22%
Nov 10, 2025David NierengartenWedbush$38.00$34.769.32%7.56%
Oct 15, 2025Stifel Nicolaus$16.00$16.58-3.50%-54.71%
Sep 02, 2025Raymond James$30.00$12.00150.00%-15.09%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 18, 2026Piper SandlerOverweightOverweighthold
Jan 07, 2026UBSBuyinitialise
Jan 06, 2026H.C. WainwrightBuyBuyhold
Dec 30, 2025Raymond JamesStrong BuyStrong Buyhold
Dec 08, 2025JefferiesBuyBuyhold
Dec 08, 2025Raymond JamesStrong BuyStrong Buyhold
Nov 11, 2025Raymond JamesStrong BuyStrong Buyhold
Nov 10, 2025WedbushOutperformupgrade
Sep 02, 2025Raymond JamesStrong Buyinitialise
Aug 25, 2025GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.42$-2.46$-2.16---
Avg Forecast$-2.32$-2.43$-2.31$-1.72$-0.66$0.71
High Forecast$-1.89$-2.30$-1.82$-1.39$0.69$0.71
Low Forecast$-2.48$-2.54$-2.74$-2.59$-1.77$0.71
Surprise %4.31%1.23%-6.49%---

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$1.51M$70.04M$258.92M$490.88M
High Forecast--$1.51M$70.04M$258.92M$490.88M
Low Forecast--$1.51M$70.04M$258.92M$490.88M
Surprise %------

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-192.41M$-255.86M$-328.94M---
Avg Forecast$-192.41M$-192.73M$-181.93M$-158.60M$-50.94M$56.56M
High Forecast$-150.89M$-183.13M$-145.21M$-111.02M$54.96M$56.56M
Low Forecast$-197.68M$-202.32M$-218.65M$-206.18M$-140.99M$56.56M
Surprise %-32.76%80.80%---

COGT Forecast FAQ

Is Cogent Biosciences stock a buy?

Cogent Biosciences stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cogent Biosciences is a favorable investment for most analysts.

What is Cogent Biosciences's price target?

Cogent Biosciences's price target, set by 12 Wall Street analysts, averages $48.13 over the next 12 months. The price target range spans from $35 at the low end to $60 at the high end, suggesting a potential 36.23% change from the previous closing price of $35.33.

How does Cogent Biosciences stock forecast compare to its benchmarks?

Cogent Biosciences's stock forecast shows a 36.23% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cogent Biosciences over the past three months?

  • March 2026: 15.38% Strong Buy, 69.23% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 15.38% Strong Buy, 69.23% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Cogent Biosciences’s EPS forecast?

Cogent Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.72, marking a -20.37% decrease from the reported $-2.16 in 2025. Estimates for the following years are $-0.66 in 2027, and $0.71 in 2028.

What is Cogent Biosciences’s revenue forecast?

Cogent Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $70.04M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $258.92M, and $490.88M for 2028.

What is Cogent Biosciences’s net income forecast?

Cogent Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-159M, representing a -51.78% decrease from the reported $-329M in 2025. Projections indicate $-50.942M in 2027, and $56.56M in 2028.